GKB Ophthalmics half-year profit rises to Rs 3.08 crore

GKB Ophthalmics Limited reported consolidated profit of Rs 3.08 crore for the half year ended September 30, 2026, compared with Rs 1.20 crore a year earlier, as revenue from operations rose to Rs 65.79 crore and net operating cash flow reached Rs 8.74 crore from Rs 1.03 crore.

How did GKB Ophthalmics perform in the first half?

GKB Ophthalmics recorded total income of Rs 67.13 crore for the half year ended September 30, 2026, up from Rs 63.06 crore in the corresponding 2025 period. Revenue from operations increased by Rs 3.31 crore year on year to Rs 65.79 crore, while other income rose to Rs 1.35 crore from Rs 57.81 lakh.

Profit before tax was Rs 3.95 crore, compared with Rs 1.35 crore in the half year ended September 30, 2025. The group’s share of loss from its associate widened to Rs 13.03 lakh from Rs 4.24 lakh, but this was outweighed by the increase in profit before the associate loss, exceptional items and tax to Rs 4.08 crore from Rs 1.39 crore.

Tax expense for the six-month period was Rs 87.25 lakh, against Rs 14.92 lakh a year earlier. After that charge, profit for the period more than doubled to Rs 3.08 crore from Rs 1.20 crore, while profit attributable to owners of the parent increased to Rs 1.67 crore from Rs 53.27 lakh.

What changed in GKB Ophthalmics' September quarter?

GKB Ophthalmics reported revenue from operations of Rs 32.75 crore for the quarter ended September 30, 2026, up from Rs 30.17 crore in the September 2025 quarter but below Rs 33.04 crore in the preceding June 2026 quarter. Total income was Rs 33.37 crore, compared with Rs 30.54 crore a year earlier and Rs 33.77 crore in June 2026.

Profit for the September 2026 quarter was Rs 1.22 crore, against Rs 1.84 crore in both the June 2026 quarter and the September 2025 quarter. Profit before tax was Rs 1.91 crore, compared with Rs 2.04 crore in June 2026 and Rs 1.91 crore a year earlier, indicating that the first-half profit improvement was concentrated in the June quarter.

Profit attributable to owners of the parent was Rs 66.12 lakh in the September quarter, compared with Rs 1.01 crore in June 2026 and Rs 53.27 lakh a year earlier. Basic earnings per share were Rs 1.31 for the September 2026 quarter, versus Rs 2.00 in June 2026 and Rs 3.17 in the September 2025 quarter; the reported interim figures are not annualised.

Why did GKB Ophthalmics' operating cash flow increase?

GKB Ophthalmics generated net cash from operating activities of Rs 8.74 crore in the half year ended September 30, 2026, compared with Rs 1.03 crore in the prior-year period. Cash generated from operations rose to Rs 8.35 crore from Rs 1.18 crore, and net income-tax paid or refunded was an inflow of Rs 38.21 lakh rather than an outflow of Rs 14.81 lakh.

Trade receivables generated Rs 1.97 crore of cash in the 2026 first half, whereas they used Rs 4.67 crore in the comparable 2025 period. Financial assets generated Rs 79.93 lakh, compared with Rs 5.32 lakh, while inventory consumed Rs 1.48 crore, substantially less than the Rs 6.23 crore cash use reported a year earlier.

Some working-capital movements moved in the other direction. Trade payables declined by Rs 1.00 crore after generating Rs 9.80 crore in the prior-year period, while other current liabilities increased by Rs 4.52 crore, compared with an increase of Rs 3.69 crore in the first half of 2025.

What does GKB Ophthalmics' September 2026 balance sheet show?

GKB Ophthalmics had cash and cash equivalents of Rs 9.59 crore on September 30, 2026, up from Rs 2.67 crore on March 31, 2026. The Rs 6.92 crore increase during the half year reflected the Rs 8.74 crore operating inflow, Rs 12.64 lakh investing inflow and Rs 1.94 crore financing outflow.

Total borrowings fell to Rs 10.65 crore at September 30 from Rs 11.66 crore at March 31, 2026. Non-current borrowings declined to Rs 1.12 crore from Rs 1.57 crore, while current borrowings decreased to Rs 9.54 crore from Rs 10.08 crore.

Inventories increased to Rs 56.11 crore from Rs 54.63 crore over the six months, while trade receivables fell to Rs 43.02 crore from Rs 44.87 crore. Total equity, including non-controlling interest, rose to Rs 58.48 crore from Rs 54.89 crore, and total assets increased to Rs 137.66 crore from Rs 132.17 crore.

What business and subsidiary matters did GKB Ophthalmics disclose?

GKB Ophthalmics said its operations predominantly involve manufacturing and trading unfinished ophthalmic lenses made of plastic, with management reviewing the group as one operating segment. The September 30, 2026 filing therefore contains no revenue, profit or asset breakdown by product line or geography.

GKB Ophthalmics Products FZE completed closure formalities for Prime Ophthalmics Products PTY Limited on July 2, 2026, after challenges in generating sufficient revenue and business opportunities. The group wrote off its Rs 43.50 lakh investment in Prime Ophthalmics during the quarter ended June 30, 2026, and said the entity was not material to overall group revenue, business or profitability.

The group also said employee-benefit liabilities under the newly notified labour codes resulted in an incremental Rs 1.79 crore expense for the year ended March 31, 2026. That amount was reported as an exceptional item, and GKB Ophthalmics said it continues to monitor the finalisation of central and state rules and government clarifications for any future accounting effect.

Conclusion

GKB Ophthalmics combined higher first-half revenue of Rs 65.79 crore with consolidated profit of Rs 3.08 crore and operating cash generation of Rs 8.74 crore. Receivables became a cash source and inventory absorbed less cash than a year earlier, although September-quarter profit was below both the June 2026 and September 2025 levels.

The next disclosed matter to watch is the accounting effect, if any, of final central and state labour-code rules and related government clarifications. GKB Ophthalmics will also report whether its Rs 9.59 crore cash balance, Rs 56.11 crore inventory position and Rs 10.65 crore borrowings change after September 30, 2026.